Fate Therapeutics (FATE) Current Deferred Revenue (2012 - 2026)

Fate Therapeutics (FATE) has 15 years of Current Deferred Revenue data on file, last reported at $582000.0 in Q1 2026.

• Quarterly Current Deferred Revenue rose 174.53% year-over-year to $582000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $582000.0 (up 174.53% YoY) and the FY2025 annual result came in at $381000.0, down 3.05% from the prior year.
• Current Deferred Revenue improved to $582000.0 in Q1 2026, from $381000.0 in the prior quarter.
• In the past five years, Current Deferred Revenue ranged from a high of $42.2 million in Q4 2022 to a low of $5000.0 in Q3 2025.
• A 5-year average of $9.4 million and a median of $685000.0 in 2023 frame the typical range for Current Deferred Revenue.
• Annual changes were most pronounced in 2025 — Current Deferred Revenue slumped 99.17% — and 2026, when it jumped 174.53%.
• Tracing FATE's Current Deferred Revenue over 5 years: stood at $42.2 million in 2022, then slumped by 98.38% to $685000.0 in 2023, then sank by 42.63% to $393000.0 in 2024, then dropped by 3.05% to $381000.0 in 2025, then soared by 52.76% to $582000.0 in 2026.
• The last three Current Deferred Revenue figures came in at $582000.0 (Q1 2026), $381000.0 (Q4 2025), and $5000.0 (Q3 2025), per Business Quant data.